ABSTRACT
Results of the patients quality of life (QL) estimation, while presence of a renal-cell cancer metastasis in the bones, using questionnaire QLQ-C30 and Karnofsky index, as well as the pain visual-analogue scale on background of treatment with bisphosphonates (BPH), were adduced. After conclusion of the combined treatment the general state improvement, a trustworthy reduction of the pain syndrome severity, as well as the patients' psychoemotional and social state, were noted. Complex treatment of patients, using BPH, have promoted a positive impact on their QL as well as a reduction of a skeleton complications rate.
Subject(s)
Bone Density Conservation Agents/therapeutic use , Bone Neoplasms/drug therapy , Carcinoma, Renal Cell/drug therapy , Diphosphonates/therapeutic use , Kidney Neoplasms/drug therapy , Pain/drug therapy , Quality of Life/psychology , Bone Neoplasms/psychology , Bone Neoplasms/secondary , Carcinoma, Renal Cell/psychology , Carcinoma, Renal Cell/secondary , Constipation/physiopathology , Constipation/prevention & control , Diarrhea/physiopathology , Diarrhea/prevention & control , Fatigue/physiopathology , Fatigue/prevention & control , Female , Humans , Kidney Neoplasms/pathology , Kidney Neoplasms/psychology , Male , Middle Aged , Motor Activity , Nausea/physiopathology , Nausea/prevention & control , Pain/pathology , Pain/psychology , Pain Measurement , Prospective Studies , Surveys and QuestionnairesABSTRACT
Diagnostic significance of estimation of the tartratresistent acid phosphatase (bone TRAP--5b) activity was studied for prognosis of occurrence of metastases in bones (MB) in patients with a renal-cell cancer (RCC). The risk of the MB occurrence was determined in patients after surgical treatment. A skeleton affection rate in patients, to whom zolendronic acid was prescribed, was trustworthy bigger, than such while conduction of treatment. So, application of bisphosphonates is recommended, in particular--zolendronic acid in dosage 4 mg every month under control of the bone TRAP--5b activity with objective of prophylaxis of the MB occurrence in patients, suffering RCC. But, we recommend for the MB diagnosis the method of determination of this marker activity as additional one while examining patients together with standard methods, including osteoscintigraphy, computer tomography.
Subject(s)
Acid Phosphatase/genetics , Biomarkers, Tumor/genetics , Bone Density Conservation Agents/therapeutic use , Bone Neoplasms/prevention & control , Carcinoma, Renal Cell/prevention & control , Diphosphonates/therapeutic use , Imidazoles/therapeutic use , Isoenzymes/genetics , Kidney Neoplasms/surgery , Aged , Bone Neoplasms/genetics , Bone Neoplasms/secondary , Bone Neoplasms/surgery , Carcinoma, Renal Cell/genetics , Carcinoma, Renal Cell/secondary , Carcinoma, Renal Cell/surgery , Drug Administration Schedule , Female , Gene Expression , Humans , Kidney Neoplasms/diagnostic imaging , Kidney Neoplasms/genetics , Kidney Neoplasms/pathology , Male , Middle Aged , Radiography , Tartrate-Resistant Acid Phosphatase , Tomography, Emission-Computed , Treatment Outcome , Zoledronic AcidABSTRACT
Determination of serum markets of bone resorption in patients, with renal cancer after radical surgery can improve the accuracy of early diagnosis of bone metastases, assess the extent of metastatic bone lesions, and monitoring of bisphosphonates treatment. These data suggest promising activity for tartrat-resistant acid phosphatase (TRAP-5b) of early detection of bone metastasis.
